carmustine has been researched along with Hodgkin Disease in 237 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)." | 9.11 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 9.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 7.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 6.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 5.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Bacteremia was documented in two patients in the O+R group and six in the control group (p=0." | 5.30 | Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 5.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| "We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)." | 5.11 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 5.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "A retrospective study of 30 cases of Hodgkin disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy with PBSC support was performed." | 3.70 | Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease. ( Bogart, JA; Chung, CT; Ryu, S; Ungureanu, C; Zamkoff, KW, 2000) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 3.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 2.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Several single-institution pilot studies have suggested that augmented preparative regimens, including those containing total body irradiation combined with an autologous bone marrow transplantation, are superior to standard regimens for the treatment of relapsed or refractory Hodgkin disease." | 2.71 | The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. ( Bolwell, BJ; Fisher, RI; Forman, SJ; LeBlanc, M; McCall, AR; Nademanee, AP; Stiff, PJ; Unger, JM, 2003) |
| "A decreased incidence of interstitial pneumonitis as well as a possible benefit in efficacy has been reported with lomustine (CCNU) compared to BCNU in the standard dose setting." | 2.70 | Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. ( Blume, KG; Chao, NS; Horning, SJ; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM, 2001) |
| "Patients with refractory or relapsing Hodgkin's disease were randomized to receive the Dexa-BEAM regimen with escalating etoposide doses supported by placebo or granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 2.70 | Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. ( Diehl, V; Ehninger, G; Franklin, J; Hasenclever, D; Kirchner, H; Koch, P; Lathan, B; Loeffler, M; Pfreundschuh, M; Rueffer, U; Schmitz, N; Sextro, M; Tesch, H, 2001) |
| "Fifteen patients with Hodgkin's disease (n = 10) and non-Hodgkin's lymphoma (n = 5) were studied." | 2.69 | Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. ( Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M, 2000) |
| " We reviewed the AUC of CPA in 470 patients who underwent pharmacokinetic monitoring of the drug." | 2.69 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Murphy, J; Nieto, Y; Shpall, EJ; Xu, X, 1999) |
| "Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7." | 2.68 | High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995) |
| "Twenty-three patients were treated in first relapse and 10 in second or subsequent relapse; 21 received mini-BEAM as their first salvage regimen." | 2.68 | Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. ( Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM, 1995) |
| "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy." | 2.68 | High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. ( Barnett, MJ; Fairey, RN; Hogge, DE; Klasa, RJ; Klingemann, HG; Nantel, SH; Reece, DE; Shepherd, JD; Sutherland, HJ; Voss, NJ, 1995) |
| "Six patients, four with Hodgkin's disease and two with non-Hodgkin lymphomas, developed leukemic complications, myelodysplasia (MDS) in four cases and overt acute myeloid leukemia (AML) in two." | 2.68 | High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. ( Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J, 1997) |
| "Asymptomatic patients with Hodgkin's disease involving at most one extranodal site whose disease is controlled by conventional dose chemotherapy or radiation therapy at the time of HDC have good outcomes after this therapy." | 2.68 | High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. ( Antin, J; Antman, K; Ault, K; Ayash, L; Bierer, B; Churchill, WH; Eder, JP; Eickhoff, C; Elias, A; Ferrara, J; Frei, E; Gaynes, L; Gilliland, G; Guinan, E; Ibrahim, J; Kadin, M; Mauch, P; Mazanet, R; McCauley, M; Parsons, S; Rimm, IJ; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1997) |
| "Of the patients with Hodgkin's disease, 2 (17%) achieved complete response (CR), and 3 (25%) attained a partial response (PR) for an overall response rate (CR + PR) of 42%." | 2.67 | Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study. ( Glick, JH; Gordon, LI; Horton, J; Rowe, JM; Smith, TJ; Spiers, AS; Weens, JH, 1991) |
| "Fourteen patients with relapsed Hodgkin's disease responded to a salvage therapy with Dexa-BEAM (dexamethasone, BCNU, etoposide, Ara-C and melphalan)." | 2.67 | Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. ( Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B, 1992) |
| " Nevertheless, we found a dose-response effect in these patients with relapsed and resistant Hodgkin's disease." | 2.67 | Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. ( Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D, 1993) |
| "Twenty-four patients with Hodgkin's disease were treated with high-dose chemotherapy and ABMT." | 2.67 | Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease. ( Bennett, C; Gopal, A; Gopal, R; Gulati, S; Toia, M, 1993) |
| "We present 155 poor-risk Hodgkin's disease patients who received high-dose BEAM (BCNU, etoposide, cytosine arabinoside, and melphalan) chemotherapy and ABMT who have been studied over a period of 8 years." | 2.67 | The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. ( Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S, 1993) |
| "Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT." | 2.67 | Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Cabanillas, F; Dicke, KA; Hagemeister, F; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Velásquez, W, 1993) |
| "Thirty-one patients with resistant Hodgkin's disease were treated by an identical high dose chemotherapy regimen and autologous bone marrow transplantation." | 2.66 | GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. ( Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K, 1989) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| " There were no differences in dosage of these two agents between patients who remain alive in CR and those who relapsed and died." | 2.65 | Simultaneous low-dose radiation and low-dose chemotherapy in the treatment of advanced Hodgkin's disease. ( Gomez, GA; Han, T; Henderson, ES; Ozer, H; Panahon, AM; Stutzman, L, 1984) |
| "Of 209 Hodgkin's disease patients treated at least 6 months with a five-drug combination of induction chemotherapy and having a complete remission, four patients developed acute myelogenous leukemia (AML) as a second malignant neoplasm." | 2.65 | Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease. ( Bartolucci, AA; Durant, JR; Gams, RA; Liu, C, 1983) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Treatment of disseminated Hodgkin's disease still fails in about 50 percent of the cases." | 2.38 | [Treatment of relapses and failures in disseminated Hodgkin's disease]. ( Bastion, Y; Coiffier, B; Tigaud, JD, 1991) |
| "The treatment of Hodgkin's disease after relapse from chemotherapy or when resistant to chemotherapy rarely results in cure." | 2.38 | What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease? ( Goldstone, A; McMillan, A, 1991) |
| "Twenty three patients with Hodgkin's disease were treated with BCNU (carmustine), etoposide, and cyclophosphamide at doses of 450-600 mg/m2, 1500-2000 mg/m2, and 120 mg/kg respectively." | 2.38 | High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. ( Ahmed, T; Arlin, ZA; Ascensao, J; Ciavarella, D; Coleman, M; Engelking, C; Feldman, E; Gingrich, S; Hussain, F; Mittelman, A, 1989) |
| "Ninety-two patients with Hodgkin lymphoma and 47 with non-Hodgkin lymphoma were enrolled." | 1.43 | LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. ( Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R, 2016) |
| "Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses." | 1.42 | Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ( Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B, 2015) |
| "Modern treatment of Hodgkin's lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause." | 1.40 | Risk of premature menopause after treatment for Hodgkin's lymphoma. ( Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV, 2014) |
| "Its efficacy in non-Hodgkin lymphoma is more modest." | 1.38 | Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. ( Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K, 2012) |
| "Stomatitis, including oral mucositis and ulcerations induced by HSV-reactivation are major sources of morbidity after high-dose (HD) chemotherapy and subsequent autologous hematopoietic stem cell transplantation (SCT)." | 1.37 | Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. ( Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U, 2011) |
| "Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed." | 1.36 | Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. ( Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G, 2010) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "Spinal cord compression was diagnosed in 33 patients with Hodgkin's disease." | 1.35 | [Clinical features and combined treatment of the central nervous system in Hodgkin's disease]. ( Filatova, LV; Gershanovich, ML, 2008) |
| "Cure rates of Hodgkin's disease (HD) with chemotherapy and/or radiotherapy are high." | 1.34 | [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. ( Al-Ali, HK; Niederwieser, D; Wittekind, C, 2007) |
| "Patients who had disease bulk at recurrence that measured > 5 cm received involved-field radiation post-ASCT." | 1.33 | Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation ( Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R, 2006) |
| " BEAM allogeneic transplantation with early reduction in immunosuppression is safe (no treatment-related deaths) and effective in advanced Hodgkin's disease where autografts have failed." | 1.32 | BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. ( Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA, 2003) |
| "46 patients with Hodgkin's disease received Dexa-BEAM chemotherapy followed by radiotherapy." | 1.31 | [The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)]. ( Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL, 2000) |
| "We transplanted 42 patients with Hodgkin's disease between 1990-1998." | 1.31 | [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. ( Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O, 2000) |
| "The probability of disease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P =." | 1.31 | Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. ( Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G, 2002) |
| "In 1995-1999, 67 patients with relapsed Hodgkin's disease or refractory to chemotherapy (group A--first relapse, B--primary refractory disease, and C--repeated relapse) received cytoreductive (dexaBEAM, DHAP) therapy followed by high-dose BEAM chemotherapy and autologous bone marrow or blood cell transplantation." | 1.31 | [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease]. ( Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA, 2000) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 1.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| " The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT." | 1.31 | High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. ( Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E, 2001) |
| " Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities." | 1.31 | A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. ( Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001) |
| "Bacteremia was documented in two patients in the O+R group and six in the control group (p=0." | 1.30 | Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| " Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of > or = 2 adverse prognostic features at diagnosis or to a slow CR." | 1.30 | BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. ( Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B, 1997) |
| "Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF." | 1.30 | Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB, 1998) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 1.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n = 44), autologous BM plus peripheral blood stem cells (PBSC) (n = 2), PBSC (n = 1), syngeneic (n = 1), or allogeneic BM (n = 3)." | 1.29 | High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. ( Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M, 1993) |
| "In eight patients with Hodgkin's disease the number of CFU-GM collected was less than 0." | 1.28 | Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. ( Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X, 1992) |
| "CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival." | 1.28 | High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. ( Armitage, JO; Bierman, PJ; Kessinger, A; Vose, JM, 1991) |
| "Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow transplantation." | 1.28 | The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. ( Blume, KG; Chao, NJ; Hoppe, RT; Horning, SJ; Kwak, LW; Long, GD; Negrin, RS; O'Connor, P; Stallbaum, B, 1991) |
| "Fifty patients with advanced-stage Hodgkin's disease (HD) who relapsed or failed to respond to multiple regimens of combination chemotherapy were entered onto two autologous bone marrow transplantation (AuBMT) protocols." | 1.28 | Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. ( Gulati, S; Yahalom, J, 1991) |
| "We treated 58 patients (28 with non-Hodgkin's lymphoma [NHL], 30 with Hodgkin's disease [HD]) at seven dose levels of CBV." | 1.28 | Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. ( Antin, JH; Ault, KA; Bubley, GJ; Churchill, WH; Come, SE; Rappaport, JM; Rosenthal, DS; Schnipper, LE; Smith, BR; Wheeler, C, 1990) |
| "Eight patients with refractory Hodgkin's disease received intensive combination chemotherapy conditioning with cyclophosphamide, carmustine (BCNU), and etoposide (VP 16-213), and allogeneic marrow transplants." | 1.28 | Allogeneic marrow transplantation for refractory Hodgkin's disease. ( Barnett, MJ; Connors, JM; Fay, JW; Herzig, GP; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Wolff, SN, 1989) |
| " rhG-CSF dosage was gradually diminished and stopped once an adequate granulocyte count was maintained." | 1.28 | Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. ( Cabanillas, FF; Fogel, B; Hagemeister, FB; Jagannath, S; Souza, LM; Spinolo, JA; Spitzer, G; Taylor, KM; Tucker, SL, 1989) |
| "Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation." | 1.28 | High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. ( Armitage, JO; Bierman, PJ; Kessinger, A; Landmark, JD; Smith, DM; Weisenburger, DD, 1989) |
| "Sixty-one patients with relapsed Hodgkin's disease who had failed a mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)- and a doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like regimen were treated with a high-dose combination chemotherapy containing cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation (ABMT)." | 1.28 | Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Armitage, JO; Dicke, KA; Hagemeister, FB; Horwitz, LJ; Jagannath, S; Kessinger, A; Smith, K; Tucker, SL; Vaughan, WP; Velasquez, WS, 1989) |
| "Thirty patients with relapsed Hodgkin's disease were treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation." | 1.27 | High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Armitage, JO; Cabanillas, FF; Dicke, KA; Horwitz, LJ; Jagannath, S; Spitzer, G; Vellekoop, L; Zander, AR, 1986) |
| "In 11 patients with non-Hodgkin's lymphoma (NHL) there were 2 complete remissions (CRs) and 2 partial remissions (PRs), and in 6 patients with Hodgkin's disease there were 5 CRs." | 1.27 | Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. ( Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 61 (25.74) | 18.7374 |
| 1990's | 75 (31.65) | 18.2507 |
| 2000's | 52 (21.94) | 29.6817 |
| 2010's | 45 (18.99) | 24.3611 |
| 2020's | 4 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Sapelli, J | 1 |
| Filho, JS | 1 |
| Matias Vieira, GM | 1 |
| Moura, FL | 1 |
| Germano, JN | 1 |
| de Lima, VCC | 1 |
| Friend, BD | 1 |
| Muhsen, IN | 1 |
| Patel, S | 1 |
| Hill, LC | 1 |
| Lulla, P | 1 |
| Ramos, CA | 1 |
| Pingali, SR | 1 |
| Kamble, RT | 1 |
| John, TD | 1 |
| Salem, B | 1 |
| Bhar, S | 1 |
| Doherty, EE | 1 |
| Craddock, J | 1 |
| Sasa, G | 1 |
| Wu, M | 1 |
| Wang, T | 1 |
| Martinez, C | 1 |
| Krance, RA | 1 |
| Heslop, HE | 1 |
| Carrum, G | 1 |
| Cohen, YI | 1 |
| Lebel, E | 1 |
| Zimran, E | 1 |
| Shaulov, A | 1 |
| Stepensky, P | 1 |
| Grisariu, S | 1 |
| Avni, B | 1 |
| Ron-Magaña, AL | 1 |
| Fernandez-Vargas, OE | 1 |
| Barrera-Chairez, E | 1 |
| Ron-Guerrero, CS | 1 |
| Bañuelos-Ávila, AJ | 1 |
| Kürzel, S | 1 |
| Blaudszun, AR | 1 |
| Stahl, L | 1 |
| Herbst, R | 1 |
| Kroschinsky, F | 1 |
| Birkmann, J | 1 |
| Hänel, A | 1 |
| Schaefer-Eckart, K | 1 |
| Ehninger, G | 2 |
| Fiedler, F | 1 |
| Bornhäuser, M | 1 |
| Fricke, S | 1 |
| Hänel, M | 1 |
| Ozuah, NW | 1 |
| Dahmoush, HM | 1 |
| Grant, FD | 1 |
| Lehmann, LE | 1 |
| LaCasce, AS | 1 |
| Billett, AL | 1 |
| Margossian, SP | 1 |
| Saleh, K | 1 |
| Danu, A | 1 |
| Koscielny, S | 1 |
| Legoupil, C | 1 |
| Pilorge, S | 1 |
| Castilla-Llorente, C | 1 |
| Ghez, D | 1 |
| Lazarovici, J | 1 |
| Michot, JM | 2 |
| Khalife-Saleh, N | 1 |
| Lapierre, V | 1 |
| Alenxandrova, K | 1 |
| Arfi-Rouche, J | 1 |
| Bourhis, JH | 1 |
| Ribrag, V | 3 |
| Elshenawy, MA | 1 |
| Shahzad Rauf, M | 1 |
| Elhassan, TAM | 1 |
| Maghfoor, I | 2 |
| Akhtar, S | 2 |
| Nieto, Y | 2 |
| Thall, PF | 1 |
| Ma, J | 1 |
| Valdez, BC | 1 |
| Ahmed, S | 1 |
| Anderlini, P | 1 |
| Popat, U | 1 |
| Jones, RB | 2 |
| Shpall, EJ | 2 |
| Hosing, C | 1 |
| Qazilbash, M | 1 |
| Kebriaei, P | 1 |
| Alousi, A | 1 |
| Timmons, M | 1 |
| Gulbis, A | 1 |
| Myers, A | 1 |
| Oki, Y | 1 |
| Fanale, M | 1 |
| Dabaja, B | 1 |
| Pinnix, C | 1 |
| Milgrom, S | 1 |
| Champlin, R | 1 |
| Andersson, BS | 1 |
| Tsang, ES | 1 |
| Villa, D | 2 |
| Loscocco, F | 1 |
| Visani, G | 2 |
| Power, M | 1 |
| Guiducci, B | 1 |
| Clissa, C | 1 |
| Song, K | 1 |
| Toze, C | 1 |
| Abou Mourad, Y | 1 |
| Sutherland, H | 1 |
| Sanford, D | 1 |
| Nantel, SH | 4 |
| Sehn, LH | 1 |
| Scott, DW | 1 |
| Savage, KJ | 1 |
| Connors, JM | 5 |
| Gerrie, AS | 1 |
| Isidori, A | 2 |
| Sakellari, I | 2 |
| Gavriilaki, E | 1 |
| Bouziana, S | 1 |
| Constantinou, V | 1 |
| Mallouri, D | 2 |
| Vardi, A | 1 |
| Marvaki, A | 2 |
| Batsis, I | 2 |
| Sotiropoulos, D | 2 |
| Anagnostopoulos, A | 2 |
| Singer, S | 1 |
| Dean, R | 1 |
| Zhao, Q | 1 |
| Sharma, N | 1 |
| Abounader, D | 1 |
| Elder, P | 1 |
| Hofmeister, CC | 1 |
| Benson, DM | 1 |
| Rosko, A | 1 |
| Penza, S | 1 |
| Andritsos, L | 1 |
| Vasu, S | 1 |
| Jaglowski, S | 1 |
| William, BM | 3 |
| Bolwell, B | 1 |
| Pohlman, B | 2 |
| Kalaycio, M | 2 |
| Jagadeesh, D | 1 |
| Hill, B | 1 |
| Sobecks, R | 1 |
| Devine, SM | 1 |
| Majhail, NS | 1 |
| Efebera, YA | 1 |
| Salvi, F | 1 |
| Luminari, S | 1 |
| Tucci, A | 1 |
| Massidda, S | 1 |
| Liberati, AM | 1 |
| Stelitano, C | 1 |
| Zanni, M | 1 |
| Re, A | 1 |
| Centurioni, R | 1 |
| Freilone, R | 1 |
| Musuraca, G | 1 |
| Nassi, L | 1 |
| Patti, C | 2 |
| Arcari, A | 1 |
| Tani, M | 1 |
| Pulsoni, A | 1 |
| Pavone, V | 1 |
| Volpetti, S | 1 |
| Peli, A | 1 |
| Evangelista, A | 1 |
| Spina, M | 1 |
| Ladetto, M | 1 |
| Merli, F | 1 |
| Eroglu, C | 1 |
| Kaynar, L | 1 |
| Orhan, O | 1 |
| Keklik, M | 1 |
| Sahin, C | 1 |
| Yildiz, OG | 1 |
| Mentes, S | 1 |
| Kurnaz, F | 1 |
| Aslan, D | 1 |
| Sivgin, S | 1 |
| Soyuer, S | 1 |
| Eser, B | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Czyz, A | 1 |
| Lojko-Dankowska, A | 1 |
| Dytfeld, D | 1 |
| Nowicki, A | 1 |
| Gil, L | 1 |
| Matuszak, M | 1 |
| Kozlowska-Skrzypczak, M | 1 |
| Kazmierczak, M | 1 |
| Bembnista, E | 1 |
| Komarnicki, M | 1 |
| Loberiza, FR | 1 |
| Whalen, V | 1 |
| Bierman, PJ | 6 |
| Bociek, RG | 1 |
| Vose, JM | 5 |
| Armitage, JO | 9 |
| Sobol, U | 1 |
| Rodriguez, T | 1 |
| Smith, S | 1 |
| Go, A | 1 |
| Vimr, R | 1 |
| Parthasarathy, M | 2 |
| Guo, R | 1 |
| Stiff, P | 1 |
| Shankar, A | 1 |
| Hayward, J | 1 |
| Kirkwood, A | 1 |
| McCarthy, K | 1 |
| Hewitt, M | 1 |
| Morland, B | 1 |
| Daw, S | 1 |
| Labrador, J | 1 |
| Cabrero-Calvo, M | 1 |
| Pérez-López, E | 1 |
| Mateos, MV | 2 |
| Vázquez, L | 5 |
| Caballero, MD | 4 |
| García-Sanz, R | 4 |
| Swerdlow, AJ | 1 |
| Cooke, R | 1 |
| Bates, A | 1 |
| Cunningham, D | 3 |
| Falk, SJ | 1 |
| Gilson, D | 1 |
| Hancock, BW | 1 |
| Harris, SJ | 1 |
| Horwich, A | 2 |
| Hoskin, PJ | 1 |
| Linch, DC | 11 |
| Lister, A | 1 |
| Lucraft, HH | 1 |
| Radford, J | 1 |
| Stevens, AM | 1 |
| Syndikus, I | 1 |
| Williams, MV | 1 |
| Pellegrini, C | 1 |
| Maglie, R | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 1 |
| Nagai, H | 1 |
| Cioch, M | 1 |
| Jawniak, D | 1 |
| Kotwica, K | 1 |
| Wach, M | 1 |
| Mańko, J | 1 |
| Gorący, A | 1 |
| Klimek, P | 1 |
| Mazurkiewicz, E | 1 |
| Jarosz, P | 1 |
| Hus, M | 1 |
| Garfin, PM | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Advani, RH | 1 |
| Luna-Fineman, S | 1 |
| Kharbanda, S | 1 |
| Porteus, M | 1 |
| Weinberg, KI | 1 |
| Agarwal-Hashmi, R | 1 |
| Chen, YB | 1 |
| Lane, AA | 1 |
| Logan, B | 1 |
| Zhu, X | 1 |
| Akpek, G | 1 |
| Aljurf, M | 1 |
| Artz, A | 1 |
| Bredeson, CN | 1 |
| Cooke, KR | 1 |
| Ho, VT | 1 |
| Lazarus, HM | 2 |
| Olsson, R | 1 |
| Saber, W | 1 |
| McCarthy, P | 1 |
| Pasquini, MC | 2 |
| Apostolou, C | 1 |
| Konstantinou, V | 1 |
| Abela, EM | 1 |
| Douka, V | 1 |
| Karypidis, K | 1 |
| Iskas, M | 1 |
| Baliakas, P | 1 |
| Kaloyannidis, P | 1 |
| Yannaki, E | 1 |
| Kouvatseas, G | 1 |
| Smias, C | 1 |
| Caimi, PF | 1 |
| Silva Rondon, CH | 1 |
| Fu, P | 1 |
| Cooper, BW | 1 |
| Campagnaro, EL | 1 |
| Gerson, SL | 1 |
| Reese-Koc, J | 1 |
| Fox, R | 1 |
| Creger, RJ | 1 |
| de Lima, M | 1 |
| You, B | 1 |
| Salles, G | 3 |
| Bachy, E | 1 |
| Casasnovas, O | 1 |
| Tilly, H | 1 |
| Sebban, C | 1 |
| Hénin, E | 1 |
| Guitton, J | 1 |
| Tod, M | 1 |
| Freyer, G | 1 |
| Khattry, N | 2 |
| Gupta, A | 1 |
| Jain, R | 1 |
| Gore, A | 1 |
| Thippeswamy, R | 1 |
| Jeevangi, N | 1 |
| Kannan, S | 1 |
| Nair, R | 1 |
| Saikia, T | 1 |
| Głowala-Kosińska, M | 1 |
| Chwieduk, A | 1 |
| Smagur, A | 1 |
| Fidyk, W | 1 |
| Najda, J | 1 |
| Mitrus, I | 1 |
| Giebel, S | 1 |
| Rabitsch, W | 1 |
| Bojic, M | 1 |
| Wohlfarth, P | 1 |
| Leiner, M | 1 |
| Schörgenhofer, C | 1 |
| Kalhs, P | 2 |
| Schulenburg, A | 1 |
| Sillaber, C | 1 |
| Mitterbauer, M | 2 |
| Sperr, WR | 1 |
| Jäger, U | 1 |
| Skrabs, K | 1 |
| Greinix, H | 1 |
| Hermann, A | 1 |
| Lamm, W | 1 |
| Flowers, CR | 1 |
| Costa, LJ | 1 |
| Le-Rademacher, J | 1 |
| Lill, M | 1 |
| Shore, TB | 1 |
| Vaughan, W | 1 |
| Craig, M | 1 |
| Freytes, CO | 2 |
| Shea, TC | 1 |
| Horwitz, ME | 1 |
| Fay, JW | 4 |
| Mineishi, S | 1 |
| Rondelli, D | 1 |
| Mason, J | 1 |
| Braunschweig, I | 1 |
| Ai, W | 1 |
| Yeh, RF | 1 |
| Rodriguez, TE | 1 |
| Flinn, I | 1 |
| Comeau, T | 1 |
| Yeager, AM | 1 |
| Pulsipher, MA | 1 |
| Bence-Bruckler, I | 1 |
| Laneuville, P | 2 |
| Bierman, P | 1 |
| Chen, AI | 1 |
| Kato, K | 1 |
| Wang, Y | 1 |
| Xu, C | 1 |
| Smith, AJ | 1 |
| Waller, EK | 1 |
| Christofides, A | 1 |
| Mazeron, R | 1 |
| Dercle, L | 1 |
| Ammari, S | 1 |
| Canova, C | 1 |
| Marabelle, A | 1 |
| Rose, S | 1 |
| Rubin, E | 1 |
| Deutsch, E | 1 |
| Soria, JC | 1 |
| Levy, A | 1 |
| Bhat, V | 1 |
| Vira, H | 1 |
| Toshniwal, M | 1 |
| Damaj, G | 1 |
| Cornillon, J | 1 |
| Bouabdallah, K | 1 |
| Gressin, R | 1 |
| Vigouroux, S | 1 |
| Gastinne, T | 1 |
| Ranchon, F | 1 |
| Ghésquières, H | 1 |
| Yakoub-Agha, I | 1 |
| Gyan, E | 1 |
| Filatova, LV | 1 |
| Gershanovich, ML | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Sperotto, A | 1 |
| Damiani, D | 1 |
| Zaja, F | 1 |
| Patriarca, F | 1 |
| Geromin, A | 1 |
| Cerno, M | 1 |
| Stocchi, R | 1 |
| Tiribelli, M | 1 |
| Skert, C | 1 |
| Rinaldi, C | 1 |
| Fanin, R | 1 |
| Eckrich, MJ | 1 |
| Domm, J | 1 |
| Ho, R | 1 |
| Whitlock, JA | 1 |
| Frangoul, H | 1 |
| González-López, TJ | 1 |
| Hermida, G | 1 |
| Graciani, IF | 1 |
| San Miguel, JF | 4 |
| Kuruvilla, J | 3 |
| Arai, S | 1 |
| Letsinger, R | 1 |
| Wong, RM | 2 |
| Johnston, LJ | 2 |
| Laport, GG | 1 |
| Lowsky, R | 1 |
| Miklos, DB | 1 |
| Shizuru, JA | 2 |
| Weng, WK | 1 |
| Lavori, PW | 1 |
| Blume, KG | 3 |
| Negrin, RS | 3 |
| Horning, SJ | 3 |
| Lane, N | 1 |
| Donaldson, MR | 1 |
| Stetson, CL | 1 |
| Smith, JL | 1 |
| Rüping, MJ | 1 |
| Keulertz, C | 1 |
| Vehreschild, JJ | 1 |
| Lövenich, H | 1 |
| Söhngen, D | 1 |
| Wieland, U | 1 |
| Cornely, OA | 2 |
| Harris, RE | 1 |
| Termuhlen, AM | 1 |
| Smith, LM | 1 |
| Lynch, J | 1 |
| Henry, MM | 1 |
| Perkins, SL | 1 |
| Gross, TG | 1 |
| Warkentin, P | 1 |
| Vlachos, A | 1 |
| Harrison, L | 1 |
| Cairo, MS | 1 |
| Samaras, P | 1 |
| Buset, EM | 1 |
| Siciliano, RD | 1 |
| Haile, SR | 1 |
| Petrausch, U | 1 |
| Mischo, A | 1 |
| Honegger, H | 2 |
| Pestalozzi, BC | 1 |
| Schanz, U | 1 |
| Stussi, G | 1 |
| Stahel, RA | 2 |
| Knuth, A | 1 |
| Renner, C | 1 |
| Stenner-Liewen, F | 1 |
| Paris, A | 1 |
| Dib, M | 1 |
| Rousselet, MC | 1 |
| Urban, T | 1 |
| Tazi, A | 1 |
| Gagnadoux, F | 1 |
| Pielichowski, W | 1 |
| Barzal, J | 1 |
| Gawronski, K | 2 |
| Mlot, B | 1 |
| Oborska, S | 2 |
| Wasko-Grabowska, A | 2 |
| Rzepecki, P | 2 |
| Barzał, J | 1 |
| Młot, B | 1 |
| Szczylik, C | 1 |
| Seshadri, T | 1 |
| Puig, N | 1 |
| Massey, C | 1 |
| Tsang, R | 2 |
| Keating, A | 4 |
| Crump, M | 3 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Bruno, A | 1 |
| Niscola, P | 1 |
| De Angelis, V | 1 |
| Datturi, T | 1 |
| Cantoni, F | 1 |
| De Meis, I | 1 |
| Dentamaro, T | 1 |
| de Fabritiis, P | 1 |
| Moore, S | 1 |
| Kayani, I | 1 |
| Peggs, K | 1 |
| Qian, W | 1 |
| Lowry, L | 1 |
| Thomson, K | 1 |
| Ardeshna, K | 1 |
| García-Lozano, T | 1 |
| Lorente Alegre, P | 1 |
| Juan Bañón, JL | 1 |
| Aznar Oroval, E | 1 |
| Glossmann, JP | 3 |
| Josting, A | 4 |
| Pfistner, B | 2 |
| Paulus, U | 1 |
| Engert, A | 4 |
| Robinson, SP | 1 |
| Goldstone, AH | 12 |
| Mackinnon, S | 1 |
| Carella, A | 1 |
| Russell, N | 1 |
| de Elvira, CR | 1 |
| Taghipour, G | 2 |
| Schmitz, N | 8 |
| Aleĭnikova, OV | 2 |
| Strongin, IuS | 1 |
| Pochetukhin, KV | 1 |
| Garau, M | 1 |
| Relaño, MT | 1 |
| Molina, L | 1 |
| del Palacio, A | 1 |
| Cooney, JP | 1 |
| Stiff, PJ | 2 |
| Toor, AA | 1 |
| Østby, I | 1 |
| Rusten, LS | 1 |
| Kvalheim, G | 3 |
| Grøttum, P | 1 |
| Unger, JM | 1 |
| Forman, SJ | 1 |
| McCall, AR | 1 |
| LeBlanc, M | 1 |
| Nademanee, AP | 1 |
| Bolwell, BJ | 3 |
| Fisher, RI | 1 |
| Qazilbash, MH | 1 |
| Devetten, MP | 1 |
| Abraham, J | 1 |
| Lynch, JP | 2 |
| Beall, CL | 1 |
| Auber, M | 1 |
| Weisenborn, R | 1 |
| Bunner, P | 1 |
| Ericson, SG | 1 |
| Dawson, LA | 1 |
| Saito, NG | 1 |
| Ratanatharathorn, V | 1 |
| Uberti, JP | 1 |
| Adams, PT | 1 |
| Ayash, LJ | 1 |
| Reynolds, CM | 1 |
| Silver, SM | 1 |
| Schipper, MJ | 1 |
| Lichter, AS | 1 |
| Eisbruch, A | 1 |
| Martín, A | 3 |
| Pérez-Simón, JA | 3 |
| López-Holgado, N | 1 |
| Cañizo, MC | 1 |
| Miguel, JF | 1 |
| Tartarone, A | 1 |
| Gallucci, G | 1 |
| Cammarota, A | 1 |
| Romano, G | 1 |
| Ardito, R | 1 |
| Di Renzo, N | 1 |
| Rudolph, C | 1 |
| Mapara, M | 2 |
| Sieniawski, M | 2 |
| Sienawski, M | 1 |
| Sieber, M | 2 |
| Kirchner, HH | 1 |
| Dörken, B | 2 |
| Hossfeld, DK | 1 |
| Kisro, J | 2 |
| Metzner, B | 2 |
| Berdel, WE | 1 |
| Diehl, V | 7 |
| Staak, O | 1 |
| Nogova, L | 1 |
| Peters, N | 1 |
| Ko, Y | 1 |
| Prince, HM | 1 |
| Regester, G | 1 |
| Gates, P | 1 |
| Jablonskis, L | 1 |
| Seymour, JF | 1 |
| Lillie, K | 1 |
| West, R | 1 |
| Wolf, M | 1 |
| Januszewicz, H | 1 |
| Belford, D | 1 |
| Strobel, ES | 1 |
| Bauchmüller, K | 1 |
| Schmitt-Gräff, A | 1 |
| Engelhardt, M | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Sastry, P | 1 |
| Bhagwat, R | 1 |
| Biswas, G | 1 |
| Khadwal, A | 1 |
| Narayanan, P | 1 |
| Bakshi, A | 1 |
| Parikh, P | 1 |
| Nagy, T | 1 |
| Pintilie, M | 1 |
| Assouline, S | 1 |
| Sylvestre, MP | 1 |
| Carriere, P | 1 |
| Shustik, C | 1 |
| Hagberg, H | 1 |
| Gisselbrecht, C | 4 |
| Canales, MA | 3 |
| Caballero, D | 2 |
| Hernandez-Navarro, F | 3 |
| Castagna, L | 1 |
| Magagnoli, M | 1 |
| Balzarotti, M | 1 |
| Sarina, B | 1 |
| Siracusano, L | 1 |
| Nozza, A | 1 |
| Todisco, E | 1 |
| Bramanti, S | 1 |
| Mazza, R | 1 |
| Russo, F | 1 |
| Timofeeva, I | 1 |
| Santoro, A | 3 |
| Torjman, L | 1 |
| Ladeb, S | 1 |
| Lakhal, A | 1 |
| Ben Othman, T | 1 |
| Abdelkefi, A | 1 |
| Ben Abdeladhim, A | 1 |
| Thomson, KJ | 1 |
| Peggs, KS | 1 |
| Blundell, E | 1 |
| El Weshi, A | 1 |
| Abdelsalam, M | 1 |
| Hussaini, H | 1 |
| Janabi, I | 1 |
| Rahal, M | 1 |
| Al-Ali, HK | 1 |
| Wittekind, C | 1 |
| Niederwieser, D | 1 |
| Benekli, M | 1 |
| Smiley, SL | 1 |
| Younis, T | 1 |
| Czuczman, MS | 1 |
| Hernandez-Ilizaliturri, F | 1 |
| Bambach, B | 1 |
| Battiwalla, M | 1 |
| Padmanabhan, S | 1 |
| McCarthy, PL | 1 |
| Hahn, T | 1 |
| Otrock, ZK | 1 |
| Beydoun, A | 1 |
| Barada, WM | 1 |
| Masroujeh, R | 1 |
| Hourani, R | 1 |
| Bazarbachi, A | 1 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Murphy, F | 1 |
| Arkenau, T | 1 |
| Norman, A | 1 |
| Oates, J | 1 |
| Wotherspoon, A | 1 |
| Bakemeier, RF | 2 |
| Anderson, JR | 2 |
| Costello, W | 2 |
| Rosner, G | 1 |
| Horton, J | 2 |
| Glick, JH | 3 |
| Hines, JD | 1 |
| Berard, CW | 1 |
| DeVita, VT | 4 |
| Bloomfield, CD | 1 |
| Pajak, TF | 3 |
| Glicksman, AS | 1 |
| Gottlieb, AJ | 1 |
| Coleman, M | 3 |
| Nissen, NI | 4 |
| Rafla, S | 1 |
| Stutzman, L | 5 |
| Vinciguerra, V | 1 |
| Glidewell, OJ | 2 |
| Holland, JF | 4 |
| Gomez, GA | 1 |
| Panahon, AM | 1 |
| Han, T | 1 |
| Ozer, H | 1 |
| Henderson, ES | 1 |
| Bartolucci, AA | 3 |
| Liu, C | 1 |
| Durant, JR | 5 |
| Gams, RA | 5 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Spurr, CL | 2 |
| Falkson, G | 2 |
| Brunner, K | 2 |
| Cuttner, J | 2 |
| Barnes, JM | 1 |
| Prosnitz, LR | 1 |
| Bennett, JM | 1 |
| Neiman, RS | 1 |
| Orlow, EL | 1 |
| Nademanee, A | 1 |
| Sniecinski, I | 1 |
| Schmidt, GM | 1 |
| Dagis, AC | 1 |
| O'Donnell, MR | 1 |
| Snyder, DS | 1 |
| Parker, PM | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Dranitsaris, G | 1 |
| Sutcliffe, SB | 3 |
| Reece, DE | 7 |
| Barnett, MJ | 5 |
| Shepherd, JD | 4 |
| Hogge, DE | 1 |
| Klasa, RJ | 1 |
| Sutherland, HJ | 3 |
| Klingemann, HG | 5 |
| Fairey, RN | 4 |
| Voss, NJ | 2 |
| Dreger, P | 3 |
| Klöss, M | 1 |
| Petersen, B | 1 |
| Haferlach, T | 2 |
| Löffler, H | 2 |
| Loeffler, M | 2 |
| Burns, LJ | 1 |
| Daniels, KA | 1 |
| McGlave, PB | 2 |
| Miller, WJ | 1 |
| Ramsay, NK | 1 |
| Kersey, JH | 1 |
| Weisdorf, DJ | 2 |
| Chatterjee, R | 1 |
| Mills, W | 1 |
| Katz, M | 1 |
| McGarrigle, HH | 1 |
| Khwaja, A | 1 |
| Phillips, GL | 4 |
| Colwill, R | 1 |
| Couture, F | 1 |
| Danish, R | 1 |
| Stewart, AK | 1 |
| Sutton, DM | 1 |
| Scott, JG | 2 |
| Brandwein, JM | 2 |
| Demirer, T | 1 |
| Weaver, CH | 3 |
| Buckner, CD | 3 |
| Petersen, FB | 1 |
| Bensinger, WI | 1 |
| Sanders, J | 1 |
| Clift, RA | 1 |
| Lilleby, K | 1 |
| Anasetti, C | 1 |
| Martin, P | 1 |
| Brice, P | 4 |
| Pautier, P | 1 |
| Marolleau, JP | 3 |
| Castaigne, S | 1 |
| Adkins, DR | 1 |
| Salzman, D | 1 |
| Boldt, D | 1 |
| Kuhn, J | 1 |
| Irvin, R | 1 |
| Roodman, GD | 1 |
| Lyons, R | 1 |
| Smith, L | 1 |
| LeMaistre, CF | 2 |
| Schlaifer, D | 1 |
| Attal, M | 1 |
| Huguet, F | 1 |
| Canal, P | 1 |
| Laurent, G | 1 |
| Pris, J | 1 |
| Winfield, D | 2 |
| Moir, D | 2 |
| Hancock, B | 2 |
| McMillan, A | 3 |
| Chopra, R | 3 |
| Milligan, D | 2 |
| Hudson, GV | 2 |
| Glass, B | 1 |
| Horst, HA | 1 |
| Ollech-Chwoyka, J | 1 |
| Suttorp, M | 1 |
| Gassmann, W | 1 |
| Spinelli, JJ | 2 |
| O'Reilly, S | 1 |
| Pfreundschuh, MG | 1 |
| Rueffer, U | 3 |
| Lathan, B | 2 |
| Brosteanu, O | 1 |
| Hasenclever, D | 3 |
| Haas, R | 2 |
| Kirchner, H | 3 |
| Koch, P | 2 |
| Kuse, R | 1 |
| Bagin, RG | 1 |
| Jagannath, S | 7 |
| Spitzer, G | 6 |
| Kessinger, A | 5 |
| Dicke, KA | 6 |
| Gulati, S | 2 |
| Bennett, C | 1 |
| Toia, M | 1 |
| Gopal, A | 1 |
| Gopal, R | 1 |
| Majolino, I | 1 |
| Scimè, R | 1 |
| Indovina, A | 1 |
| Vasta, S | 1 |
| Liberti, G | 1 |
| Gentile, S | 1 |
| Pisa, R | 1 |
| Caronia, F | 1 |
| McMillan, AK | 2 |
| Yuklea, S | 1 |
| Pearce, R | 1 |
| Patterson, KG | 2 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Spinolo, JA | 3 |
| Velásquez, W | 1 |
| Cabanillas, F | 2 |
| Hagemeister, F | 1 |
| Horwitz, LJ | 4 |
| Leichner, PK | 1 |
| Quadri, SM | 1 |
| Klein, JL | 1 |
| Abrams, RA | 1 |
| Vriesendorp, HM | 1 |
| Stewart, FM | 1 |
| Temeles, D | 1 |
| Lowry, P | 1 |
| Thraves, T | 1 |
| Grosh, WW | 1 |
| Quesenberry, PJ | 1 |
| Smith, RJ | 1 |
| Sweetenham, JW | 1 |
| Ahmed, T | 2 |
| Lake, D | 1 |
| Feldman, E | 2 |
| Seiter, K | 1 |
| Helson, L | 1 |
| Mittelman, A | 2 |
| Puccio, C | 1 |
| Chun, H | 1 |
| Grima, K | 1 |
| Akhtar, T | 1 |
| Boogaerts, MA | 1 |
| Ferrant, A | 3 |
| Demuynck, HM | 1 |
| Link, H | 1 |
| Zander, A | 1 |
| Barge, A | 1 |
| Lumley, MA | 1 |
| Milligan, DW | 1 |
| Knechtli, CJ | 1 |
| Long, SG | 1 |
| Billingham, LJ | 1 |
| McDonald, DF | 1 |
| Schwartzberg, L | 1 |
| Li, W | 1 |
| Hazelton, B | 1 |
| West, W | 1 |
| Raybon, KB | 1 |
| Snyder, MJ | 1 |
| Halvorson, RD | 1 |
| Freeman, MB | 1 |
| Bishop, MR | 1 |
| Rubio, C | 1 |
| Hill, ME | 1 |
| Milan, S | 3 |
| O'Brien, ME | 1 |
| Jost, LM | 1 |
| Betts, E | 1 |
| Goebel, ME | 1 |
| Nagler, A | 1 |
| Uss, AL | 3 |
| Milanovich, NF | 3 |
| Snegir', VM | 2 |
| Skriagin, AE | 2 |
| Zmachinskiĭ, VA | 3 |
| Batan, ZE | 3 |
| Wheeler, C | 3 |
| Eickhoff, C | 1 |
| Elias, A | 2 |
| Ibrahim, J | 2 |
| Ayash, L | 1 |
| McCauley, M | 1 |
| Mauch, P | 2 |
| Schwartz, G | 1 |
| Eder, JP | 1 |
| Mazanet, R | 1 |
| Ferrara, J | 1 |
| Rimm, IJ | 1 |
| Guinan, E | 1 |
| Bierer, B | 1 |
| Gilliland, G | 1 |
| Churchill, WH | 2 |
| Ault, K | 2 |
| Parsons, S | 1 |
| Antman, K | 1 |
| Schnipper, L | 1 |
| Tepler, I | 1 |
| Gaynes, L | 1 |
| Frei, E | 2 |
| Kadin, M | 1 |
| Antin, J | 2 |
| Rubio, V | 2 |
| Rifon, J | 2 |
| Heras, I | 2 |
| Vidriales, B | 2 |
| del Cañizo, MC | 1 |
| Corral, M | 1 |
| Gonzalez, M | 2 |
| León, A | 2 |
| Jean-Paul, E | 2 |
| Rocha, E | 2 |
| Moraleda, JM | 1 |
| Pedersen-Bjergaard, J | 2 |
| Pedersen, M | 1 |
| Myhre, J | 1 |
| Geisler, C | 1 |
| del Cañizo, C | 1 |
| Vicente, V | 1 |
| Goormastic, M | 1 |
| Dannley, R | 1 |
| Andresen, SW | 1 |
| Lichtin, A | 1 |
| Overmoyer, B | 1 |
| Ptuskin, VV | 1 |
| Demina, EA | 1 |
| Chervonobab, IuV | 1 |
| Tupitsyn, NN | 1 |
| Larionova, VB | 1 |
| Kondrat'eva, NE | 1 |
| Andreeva, LA | 1 |
| Mkheidze, DM | 1 |
| Chimishkian, KL | 1 |
| Salloum, E | 2 |
| Jillella, AP | 2 |
| Nadkarni, R | 2 |
| Seropian, S | 3 |
| Hu, GL | 2 |
| D'Andrea, E | 1 |
| Zelterman, D | 2 |
| Cooper, DL | 3 |
| Kàtay, I | 1 |
| Winter, S | 1 |
| Tesch, H | 3 |
| Wickramanayake, PD | 1 |
| Arranz, R | 1 |
| Tomás, JF | 1 |
| Gil-Fernández, JJ | 1 |
| Martínez-Chamorro, C | 1 |
| Granados, E | 1 |
| Alegre, A | 1 |
| Figuera, A | 1 |
| Cámara, R | 1 |
| Fernández-Rañada, JM | 1 |
| Aurlien, E | 1 |
| Holte, H | 2 |
| Pharo, A | 1 |
| Kvaløy, S | 2 |
| Jakobsen, E | 1 |
| Smeland, EB | 1 |
| Zhen, B | 1 |
| Lancet, JE | 1 |
| Rapoport, AP | 1 |
| Brasacchio, R | 1 |
| Eberly, S | 1 |
| Raubertas, RF | 1 |
| Linder, T | 1 |
| Muhs, A | 1 |
| Duerst, RE | 1 |
| Abboud, CN | 1 |
| Packman, CH | 1 |
| DiPersio, JF | 1 |
| Constine, LS | 1 |
| Rowe, JM | 2 |
| Liesveld, JL | 1 |
| Xu, X | 1 |
| Cagnoni, PJ | 1 |
| Matthes, S | 1 |
| Bearman, SI | 1 |
| Murphy, J | 1 |
| Burtness, B | 1 |
| Nevill, TJ | 1 |
| Sayegh, A | 1 |
| Brockington, DA | 1 |
| O'Reilly, SE | 1 |
| Kiss, I | 1 |
| Tomasek, J | 1 |
| Muñoz, L | 1 |
| Martino, R | 1 |
| Subirà, M | 1 |
| Brunet, S | 1 |
| Sureda, A | 1 |
| Sierra, J | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Devereux, S | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Fleming, DR | 1 |
| Wolff, SN | 2 |
| Brown, RA | 1 |
| Stevens, DA | 1 |
| Goodman, SA | 1 |
| Greer, JP | 2 |
| Stein, RS | 1 |
| Pineiro, LA | 1 |
| Collins, RH | 1 |
| Goldsmith, LJ | 1 |
| Herzig, GP | 3 |
| Herzig, RH | 3 |
| Fernández-Jiménez, MC | 2 |
| Ojeda, E | 1 |
| de Bustos, JG | 1 |
| Aguado, MJ | 1 |
| Keilholz, U | 1 |
| Szelényi, H | 1 |
| Siehl, J | 1 |
| Foss, HD | 1 |
| Knauf, W | 1 |
| Thiel, E | 1 |
| Bogart, JA | 1 |
| Ungureanu, C | 1 |
| Ryu, S | 1 |
| Chung, CT | 1 |
| Zamkoff, KW | 1 |
| Vela-Ojeda, J | 1 |
| Tripp-Villanueva, F | 1 |
| Montiel-Cervantes, L | 1 |
| Sánchez-Cortés, E | 1 |
| Ayala-Sánchez, M | 1 |
| Guevara-Moreno, ME | 1 |
| García-León, LD | 1 |
| Rosas-Cabral, A | 1 |
| Esparza, MA | 1 |
| González-Llaven, J | 1 |
| Argiris, A | 1 |
| Stroiakovskiĭ, DL | 1 |
| Pivnik, AV | 1 |
| Shavlokhov, VS | 1 |
| Sotnikov, VM | 1 |
| Moiseeva, TN | 1 |
| Rasstrigin, NA | 1 |
| Margolin, OV | 1 |
| Efimov, IV | 1 |
| Dzhumabaeva, BT | 1 |
| Kaplanskaia, IB | 1 |
| Roshchina, LS | 1 |
| Avigdor, A | 1 |
| Hardan, I | 1 |
| Shpilberg, O | 1 |
| Raanani, P | 1 |
| Grotto, I | 1 |
| Ben-Bassat, I | 1 |
| Carella, AM | 3 |
| Cavaliere, M | 1 |
| Lerma, E | 1 |
| Ferrara, R | 1 |
| Tedeschi, L | 1 |
| Romanelli, A | 1 |
| Vinci, M | 1 |
| Pinotti, G | 1 |
| Lambelet, P | 1 |
| Loni, C | 1 |
| Verdiani, S | 1 |
| De Stefano, F | 1 |
| Valbonesi, M | 1 |
| Corsetti, MT | 1 |
| Moskowitz, CH | 1 |
| Nimer, SD | 1 |
| Zelenetz, AD | 1 |
| Trippett, T | 1 |
| Hedrick, EE | 1 |
| Filippa, DA | 1 |
| Louie, D | 1 |
| Gonzales, M | 1 |
| Walits, J | 1 |
| Coady-Lyons, N | 1 |
| Qin, J | 1 |
| Frank, R | 1 |
| Bertino, JR | 1 |
| Goy, A | 1 |
| Noy, A | 1 |
| O'Brien, JP | 1 |
| Straus, D | 1 |
| Portlock, CS | 1 |
| Yahalom, J | 2 |
| Dziuba, EV | 1 |
| Vlasenkova, SV | 1 |
| Solov'eva, NS | 1 |
| Mitskevich, PB | 1 |
| Zavgorodniaia, IL | 1 |
| Zhavrid, EA | 1 |
| García de Bustos, J | 1 |
| Pfreundschuh, M | 1 |
| Sextro, M | 2 |
| Franklin, J | 1 |
| Khurshid, A | 1 |
| Weihrauch, MR | 1 |
| Re, D | 1 |
| Scheidhauer, K | 1 |
| Ansén, S | 1 |
| Dietlein, M | 1 |
| Bischoff, S | 1 |
| Bohlen, H | 1 |
| Wolf, J | 1 |
| Schicha, H | 1 |
| Stuart, MJ | 1 |
| Chao, NS | 1 |
| Long, GD | 2 |
| Stockerl-Goldstein, KE | 1 |
| Blystad, AK | 1 |
| Smeland, E | 1 |
| Delabie, J | 1 |
| Pels, H | 1 |
| Bethe, U | 1 |
| Seibold, M | 1 |
| Toepelt, K | 1 |
| Soehngen, D | 1 |
| Ritzkowsky, A | 1 |
| Fermé, C | 2 |
| Mounier, N | 1 |
| Diviné, M | 1 |
| Stamatoullas, A | 1 |
| Reman, O | 1 |
| Voillat, L | 1 |
| Jaubert, J | 1 |
| Lederlin, P | 1 |
| Colin, P | 1 |
| Berger, F | 1 |
| Becherer, A | 1 |
| Jaeger, U | 1 |
| Greinix, HT | 1 |
| Karanikas, G | 1 |
| Pötzi, C | 1 |
| Raderer, M | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Haenel, M | 1 |
| Boissevain, F | 1 |
| Zschaber, R | 1 |
| Müller, P | 1 |
| Lohri, A | 1 |
| Decker, S | 1 |
| Koch, B | 1 |
| Harrison, DT | 1 |
| Neiman, PE | 1 |
| Glidewell, O | 1 |
| Blom, J | 2 |
| Leone, L | 1 |
| Sawitsky, A | 1 |
| Haurani, F | 1 |
| Harley, JB | 1 |
| Seligman, B | 1 |
| Cornell, C | 1 |
| Henry, P | 1 |
| Senn, HJ | 2 |
| Martz, G | 1 |
| Maurice, P | 2 |
| Bank, A | 1 |
| Shapiro, L | 1 |
| James, GW | 1 |
| Schorer, AE | 1 |
| Oken, MM | 1 |
| Johnson, GJ | 1 |
| Ghatak, NR | 1 |
| Sawyer, DR | 1 |
| Velez-Garcia, E | 3 |
| Bartolucci, A | 2 |
| Wirtschafter, D | 1 |
| Dorfman, R | 1 |
| Costanzi, JJ | 1 |
| Anderson, T | 1 |
| DeVita, T | 1 |
| Young, RC | 2 |
| Dorfman, RF | 1 |
| Jochimsen, PR | 1 |
| Pearlman, NW | 1 |
| Lawton, RL | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 5 |
| Chang, TC | 1 |
| Sokal, JE | 1 |
| Dombret, H | 1 |
| Lepage, E | 2 |
| Baruchel, A | 2 |
| Adam, M | 1 |
| Miclea, JM | 1 |
| Sitthy, X | 1 |
| Hohaus, S | 1 |
| Egerer, G | 1 |
| Ehrhardt, R | 1 |
| Witt, B | 1 |
| Hunstein, W | 1 |
| Machiels, JP | 1 |
| Martiat, P | 1 |
| Doyen, C | 1 |
| Bosly, A | 1 |
| Michaux, JL | 2 |
| Harding, M | 1 |
| Selby, P | 2 |
| Gore, M | 2 |
| Perren, T | 1 |
| Treleavan, J | 1 |
| Mansi, J | 1 |
| Zulian, G | 1 |
| Meldrum, M | 1 |
| Viner, C | 1 |
| Blair, S | 1 |
| Richards, JD | 1 |
| Cervi, P | 1 |
| Kinsey, S | 1 |
| Deisseroth, A | 1 |
| Ventura, G | 1 |
| Fogel, B | 2 |
| Taylor, K | 1 |
| Huan, S | 1 |
| Dunphy, F | 1 |
| Dicke, K | 1 |
| Souza, L | 1 |
| Spiers, AS | 1 |
| Weens, JH | 1 |
| Smith, TJ | 1 |
| Gordon, LI | 1 |
| Bastion, Y | 1 |
| Tigaud, JD | 1 |
| Coiffier, B | 1 |
| Gerota, O | 1 |
| Boiron, M | 1 |
| Hurd, DD | 1 |
| Haake, RJ | 1 |
| Lasky, LC | 1 |
| Christiansen, NP | 1 |
| Bostrom, B | 1 |
| Levine, EG | 1 |
| Kim, TH | 1 |
| Peterson, BA | 1 |
| Goldstone, A | 1 |
| Chao, NJ | 1 |
| Hoppe, RT | 1 |
| Kwak, LW | 1 |
| Stallbaum, B | 1 |
| O'Connor, P | 1 |
| Schouten, HC | 1 |
| Maragos, D | 1 |
| Vose, J | 1 |
| Callum, J | 1 |
| Antin, JH | 1 |
| Come, SE | 1 |
| Smith, BR | 1 |
| Bubley, GJ | 1 |
| Rosenthal, DS | 1 |
| Rappaport, JM | 1 |
| Ault, KA | 1 |
| Schnipper, LE | 1 |
| Omura, GA | 1 |
| Kellermeyer, R | 1 |
| Raney, M | 1 |
| Taylor, KM | 1 |
| Tucker, SL | 2 |
| Cabanillas, FF | 2 |
| Hagemeister, FB | 3 |
| Souza, LM | 1 |
| Smith, DM | 1 |
| Landmark, JD | 1 |
| Weisenburger, DD | 1 |
| Hamoir, V | 1 |
| Binon, J | 1 |
| Sokal, G | 1 |
| Smith, KE | 1 |
| McLaughlin, P | 1 |
| Swan, F | 1 |
| Ciavarella, D | 1 |
| Ascensao, J | 1 |
| Hussain, F | 1 |
| Engelking, C | 1 |
| Gingrich, S | 1 |
| Arlin, ZA | 1 |
| Velasquez, WS | 1 |
| Smith, K | 1 |
| Vaughan, WP | 1 |
| Devereaux, S | 1 |
| Gribben, JG | 1 |
| Patterson, K | 1 |
| Zulian, GB | 1 |
| Nandi, A | 1 |
| Forgeson, G | 1 |
| Perren, TJ | 1 |
| McElwain, TJ | 1 |
| Williams, SF | 1 |
| Bitran, JD | 1 |
| Vellekoop, L | 1 |
| Zander, AR | 1 |
| Anderson, CC | 1 |
| Souhami, RL | 1 |
| Harper, PG | 1 |
| McLennan, KA | 1 |
| Jones, M | 1 |
| Machin, SJ | 1 |
| Jelliffe, AM | 1 |
| Cawley, JC | 1 |
| Appelbaum, FR | 1 |
| Lombard, CM | 1 |
| Churg, A | 1 |
| Winokur, S | 1 |
| Santini, G | 1 |
| Coser, P | 1 |
| Frassoni, F | 1 |
| Martinengo, M | 1 |
| Nati, S | 1 |
| Congiu, A | 1 |
| Giordano, D | 1 |
| Cerri, R | 1 |
| Goldsmith, MA | 2 |
| Carbone, PP | 2 |
| Desser, RK | 1 |
| Ultmann, JE | 1 |
| Stacher, A | 1 |
| Sahakian, GJ | 1 |
| al-Mondhiry, H | 1 |
| Lacher, MJ | 1 |
| Connolly, CE | 1 |
| McLaren, JH | 1 |
| Papac, RJ | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Schein, PS | 1 |
| O'Connell, MJ | 1 |
| Hubbard, S | 1 |
| Magrath, IT | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| Ziegler, JL | 1 |
| Schabel, FM | 1 |
| Goldin, A | 1 |
| De Vita, VT | 1 |
| Canellos, GP | 1 |
| Schein, PJ | 1 |
| Chabner, BA | 1 |
| Bagley, CM | 1 |
| Aungst, CW | 1 |
| Livingston, RB | 1 |
| Brunner, KW | 1 |
| Sonntag, RW | 1 |
| Lenhard, RE | 1 |
| Nordentoft, AM | 1 |
| Jensen, KB | 1 |
| Lessner, HE | 1 |
| Rubin, P | 1 |
| Fairley, GH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.[NCT03500133] | Phase 4 | 500 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation[NCT03315520] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-01-22 | Recruiting | ||
| Gemcitabine and High-dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease[NCT00388349] | Phase 2 | 146 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma[NCT00002941] | Phase 2 | 69 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma[NCT00271050] | Phase 1 | 12 participants (Anticipated) | Interventional | 2005-12-31 | Completed | ||
| Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation[NCT00001830] | Phase 1 | 110 participants (Actual) | Interventional | 1999-07-20 | Completed | ||
| Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma[NCT01468311] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2011-10-11 | Terminated (stopped due to Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.) | ||
| Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma[NCT00001270] | Phase 1 | 85 participants | Interventional | 1991-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reported as the number of Phase 1 participants by gemcitabine dose that experienced non-hematologic toxicity, ie, drug-related adverse events. (NCT00388349)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| 1250 mg/m2 Gemcitabine + HD Chemo + PBSC Rescue | 0 |
| 1500 mg/m2 Gemcitabine + HD Chemo + PBSC Rescue | 3 |
Reports the percentage of participants surviving 6 months after PBSC infusion (transplant). (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 87 |
Pulmonary toxicity as assessed by the number of participants that experience BCNU pneumonitis, ie, pneumonitis due to carmustine (BCNU). (NCT00388349)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 26 |
Reports the percentage of participants that experienced relapse post-transplant. (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 29 |
"Reports the survival measures:~Freedom from progression (FFP)~Event-free survival (EFS)~Overall survival (OS)~EFS and OS were estimated by Kaplan-Meier method~Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Freedom from Progression (FFP) | Event-Free Survival (EFS) | Overall Survival (OS) | |
| 1250 mg/m2 Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 71 | 67 | 83 |
Complete response rate is defined as the time it takes a participant to achieve a complete response. Response is assessed by the Revised Response Criteria for Malignant Lymphoma. Complete response requires all of the following: complete disappearance of all detectable clinical evidence of disease and disease related symptoms if present before therapy. A post treatment residual mass is permitted as long as it is positron emission tomography (PET) negative. If a pretreatment PET scan was negative, all lymph nodes and nodal masses must have regressed on computed tomography (CT) to normal size (<1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy); Previously involved nodes that were 1.1 to 1.5 cm in their long axis and more than 1.0 cm in their short axis before treatment must have decreased to <1.0 cm in their short axis after treatment. (NCT01468311)
Timeframe: 20 months post autologous stem cell transplant
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 7.5 |
DFS is defined as the amount of time participants remain disease free. (NCT01468311)
Timeframe: DFS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
Patients who develop either a Common Terminology Criteria in Adverse Events (CTCAE) v4.0 grade 3 or greater non-hematologic toxicity, with the exception of fatigue, of more than 5 days duration possibly, probably or definitely related to the infusion of 90Y-daclizumab prior to the start of Carmustine, Etoposide, Cytarabine, [Ara-C, Cytosine Arabinoside] and Melphalan (BEAM) chemotherapy (Day - 6) will have developed by definition a dose-limiting toxicity (DLT). (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 0 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 3 |
Overall survival is defined as the time from the date of registration to the date of death due to any cause or if no death occurs to the last documented information on the patient. (NCT01468311)
Timeframe: OS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
22 reviews available for carmustine and Hodgkin Disease
| Article | Year |
|---|---|
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; B | 2014 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; D | 2016 |
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Hematopoietic St | 2017 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cy | 2009 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; C | 1994 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; | 1991 |
What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1991 |
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1989 |
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Clinical studies of autologous bone marrow transplantation in Hodgkin's disease.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1986 |
Combination chemotherapy of advanced Hodgkin's disease. A review.
Topics: Bleomycin; Carmustine; Cyclohexanes; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; H | 1974 |
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singly.
Topics: Adrenal Cortex Hormones; Alopecia; Antineoplastic Agents; Bleomycin; Blood Platelet Disorders; Carmu | 1973 |
[Cytostatic chemotherapy in lymphogranulomatosis].
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; Doxorubi | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
Current chemotherapeutic combinations.
Topics: Antineoplastic Agents; Carmustine; Chlorambucil; Cyclophosphamide; Drug Evaluation; Drug Therapy, Co | 1973 |
Single-agent therapy for Hodgkin's disease.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carmustine; | 1973 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosin | 1971 |
75 trials available for carmustine and Hodgkin Disease
| Article | Year |
|---|---|
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2022 |
Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Cy | 2018 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidi | 2018 |
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity | 2019 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat | 2016 |
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 2010 |
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyc | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; E | 2011 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; E | 2002 |
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophospham | 2003 |
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; | 2004 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Comb | 2005 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cy | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2008 |
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Clinical Trials | 1984 |
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.
Topics: Adult; Antineoplastic Agents; Bleomycin; Carmustine; Doxorubicin; Drug Therapy, Combination; Female; | 1982 |
Simultaneous low-dose radiation and low-dose chemotherapy in the treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 1984 |
Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Hodgkin | 1983 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
Topics: Adult; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, | 1982 |
Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina | 1982 |
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Movement; Cohort | 1994 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyt | 1995 |
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bo | 1995 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1994 |
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 1994 |
Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1993 |
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1993 |
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1996 |
High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined M | 1996 |
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 1996 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 1997 |
Progressive disease after ABMT for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Su | 1997 |
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 1998 |
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neopl | 1999 |
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1999 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; | 1999 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; C | 2000 |
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Cyc | 2001 |
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexametha | 2001 |
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytar | 2002 |
Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone.
Topics: Adult; Blood Cell Count; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Ho | 1977 |
A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B.
Topics: Adult; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Femal | 1979 |
BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Child; Cyclophosphamide; Dr | 1978 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
Topics: Bacterial Infections; Bone Marrow; Carmustine; Clinical Trials as Topic; Hodgkin Disease; Humans; Re | 1976 |
Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
Topics: Administration, Oral; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug | 1976 |
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 1992 |
A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Doxorubic | 1992 |
Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; D | 1991 |
Alternating sequential combination chemotherapy in the management of advanced Hodgkin's disease. A Southeastern Cancer Study Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Clinical Trials as Top | 1986 |
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmus | 1989 |
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
[On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
Topics: Carmustine; Chlorambucil; Cyclohexanes; Drug Resistance; Drug Synergism; Hodgkin Disease; Humans; Ni | 1972 |
Chemotherapy of Hodgkin's disease in studies by acute leukemia group B.
Topics: Antineoplastic Agents; Carmustine; Chlorambucil; Evaluation Studies as Topic; Hodgkin Disease; Human | 1973 |
142 other studies available for carmustine and Hodgkin Disease
| Article | Year |
|---|---|
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combi | 2021 |
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabi | 2022 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2023 |
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 2019 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; | 2018 |
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuxima | 2018 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Eto | 2019 |
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; | 2019 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustin | 2015 |
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-F | 2013 |
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphami | 2013 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposi | 2014 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambuc | 2014 |
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplati | 2014 |
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |
Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Topics: Adult; Biosimilar Pharmaceuticals; Carmustine; Female; Filgrastim; Granulocyte Colony-Stimulating Fa | 2014 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Fema | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fol | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyta | 2015 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine | 2015 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide | 2016 |
Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyclophosphamid | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2016 |
Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antibiotic Prophylaxis; Antifungal Agents; | 2017 |
[Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 2002 |
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Ther | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2010 |
JAAD grand rounds quiz*: Dusky intertriginous plaques and acral erythema after bone marrow transplant.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Erythema; E | 2010 |
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Cytokines; Female; He | 2011 |
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administra | 2010 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmusti | 2011 |
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dru | 2012 |
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Cytarabine | 2012 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; | 2012 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2002 |
[Foliculitis in a patient with Hodkins disease].
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Com | 2003 |
BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyta | 2003 |
A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
Topics: Adult; Algorithms; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carm | 2003 |
High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2003 |
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contrac | 2005 |
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmust | 2005 |
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytid | 2006 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycyti | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2007 |
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Stu | 2007 |
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cohort Studies | 2007 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combin | 2008 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2008 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; C | 1995 |
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmu | 1993 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1995 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chem | 1994 |
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colo | 1993 |
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 1995 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Hemolytic uremic syndrome after autologous BMT without TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1996 |
Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Carmustine; Female; Hodgkin Disease; Humans; M | 1997 |
Carmustine and the lungs .
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Female; Hodgkin Disease; Huma | 1997 |
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Ch | 1997 |
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
[Autologous transplant with BEAM protocol in lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 1997 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1997 |
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1998 |
Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphami | 1998 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1998 |
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1998 |
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carm | 1999 |
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Etop | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; | 1999 |
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bact | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 1999 |
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combi | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Ther | 2000 |
[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2000 |
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; | 2001 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cy | 2001 |
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combi | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillo | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2002 |
Gynecomastia with nitrosourea therapy.
Topics: Adult; Aged; Carmustine; Gynecomastia; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 1978 |
A morphologic study of opportunistic cerebral toxoplasmosis.
Topics: Aged; Brain Diseases; Carmustine; Hodgkin Disease; Humans; Male; Prednisone; Procarbazine; Radionucl | 1978 |
Carmustine (BiCNU).
Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma | 1978 |
Pancreatic carcinoma as a sequel to therapy of lymphoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Carmustine; Cyclophosphamide; Female; Hodg | 1976 |
Correlation of delayed hypersensitivity responses with chemotherapeutic results in advanced Hodgkin's disease.
Topics: Carmustine; Drug Therapy, Combination; Hodgkin Disease; Hypersensitivity, Delayed; Prednisone; Proca | 1975 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Ca | 1992 |
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1992 |
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1992 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Car | 1991 |
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Specimen Co | 1990 |
Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1991 |
Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow | 1991 |
Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1990 |
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Mo | 1991 |
Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1991 |
Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Diabetes Mellitus; Dos | 1990 |
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1990 |
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
Allogeneic marrow transplantation for refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1989 |
Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stim | 1989 |
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfu | 1989 |
Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Comb | 1985 |
High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1989 |
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1989 |
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1989 |
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1986 |
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1986 |
Pulmonary veno-occlusive disease following therapy for malignant neoplasms.
Topics: Adolescent; Adult; Biopsy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Hodgkin D | 1987 |
Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Dis | 1985 |
Treatment of Hodgkin's disease.
Topics: Antineoplastic Agents; Carmustine; Cyclohexanes; Hodgkin Disease; Humans; Nitrosourea Compounds | 1973 |
International Symposium on Hodgkin's Disease. Session 4. Small group workshops. Report on workshop: Chemotherapy.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Doxorubicin; Drug Therapy, Combination; Hodgkin Diseas | 1973 |
Acute leukemia in Hodgkin's disease.
Topics: Adult; Bleomycin; Carmustine; Chlorambucil; Drug Therapy, Combination; Female; Hodgkin Disease; Huma | 1974 |
Prognosis and survival with extranodal Hodgkin's disease.
Topics: Adult; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Human | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Eastern cooperative oncology group studies.
Topics: Antineoplastic Agents; Blood Cell Count; Carmustine; Cyclophosphamide; Hodgkin Disease; Humans; Mech | 1973 |
Combination chemotherapy in Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Child; Female; Hodgkin Disease; Humans; | 1973 |
Development of four-drug BCNU combination chemotherapy regimens.
Topics: Carmustine; Cyclophosphamide; Evaluation Studies as Topic; Hematologic Diseases; Hodgkin Disease; Hu | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Management with combination therapy.
Topics: Antineoplastic Agents; Benzoates; Carmustine; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; | 1973 |
Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
Topics: Adult; Age Factors; Antineoplastic Agents; Biopsy; Carmustine; Chlorambucil; Cyclophosphamide; Dacti | 1973 |
[Progress in combination chemotherapy of malignant lymphomas (author's transl)].
Topics: Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Nitr | 1973 |